Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock
Throughout the last three months, 5 analysts have evaluated NeuroPace (NASDAQ:NPCE), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Analysts have recently evaluated NeuroPace and provided 12-month price targets. The average target is $19.0, accompanied by a high estimate of $22.00 and a low estimate of $16.00. This upward trend is apparent, with the current average reflecting a 11.76% increase from the previous average price target of $17.00.
Decoding Analyst Ratings: A Detailed Look
In examining recent analyst actions, we gain insights into how financial experts perceive NeuroPace. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Yi Chen | HC Wainwright & Co. | Raises | Buy | $19.00 | $18.00 |
| Priya Sachdeva | UBS | Raises | Buy | $22.00 | $18.00 |
| Rohin Patel | JP Morgan | Raises | Overweight | $20.00 | $18.00 |
| Rohin Patel | JP Morgan | Raises | Overweight | $18.00 | $16.00 |
| Vik Chopra | Wells Fargo | Raises | Overweight | $16.00 | $15.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NeuroPace. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of NeuroPace compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for NeuroPace's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of NeuroPace's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on NeuroPace analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About NeuroPace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Key Indicators: NeuroPace's Financial Health
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: NeuroPace's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 29.89%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -12.78%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): NeuroPace's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -18.42%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): NeuroPace's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -3.28%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.84, caution is advised due to increased financial risk.
Analyst Ratings: What Are They?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.